SuperworthImunon revenue IMNN
Sales by quarter and over the last twelve months, from 2017.
- Last 12 months, to Dec 31, 2022
- $500K
- Latest quarter, Q4 FY22
- $125K
- +0% on a year earlier
- Fiscal year 2022
- $500K
- +0% on the year before
Imunon's revenue was $500K over the twelve months to Dec 31, 2022, up 0% on a year earlier.
In its latest quarter, Q4 FY22, it was $125K, up 0% on the same quarter a year before.
Over the five fiscal years to FY2022 it grew 0% a year on average.
Revenue over time
Fiscal year by fiscal year
| Fiscal year | Revenue | Change |
|---|---|---|
| FY2022 | $500K | +0% |
| FY2021 | $500K | +0% |
| FY2020 | $500K | +0% |
| FY2019 | $500K | +0% |
| FY2018 | $500K | +0% |
| FY2017 | $500K | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | Revenue | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q4 FY22 | $125K | +0% | $500K | |
| Q3 FY22 | $125K | +0% | $500K | |
| Q2 FY22 | $125K | +0% | $500K | |
| Q1 FY22 | $125K | +0% | $500K | |
| Q4 FY21 | $125K | +0% | $500K | |
| Q3 FY21 | $125K | +0% | $500K | |
| Q2 FY21 | $125K | +0% | $500K | |
| Q1 FY21 | $125K | +0% | $500K | |
| Q4 FY20 | $125K | +0% | $500K | |
| Q3 FY20 | $125K | +0% | $500K | |
| Q2 FY20 | $125K | +0% | $500K | |
| Q1 FY20 | $125K | +0% | $500K |
Against its peers
Companies in Healthcare nearest Imunon's size, closest first, today.
| Company | Revenue, 12 months | Growth |
|---|---|---|
| IMNNImunon | n/m | |
| NEPHNephros | $20.7M | +24% a year |
| ATNMActinium Pharmaceuticals | n/m | |
| APTAlpha Pro Tech | $61.9M | +6% a year |
| SPROSpero Therapeutics | $47M | −3% a year |
| Peer median | $47M |
What the revenue tells you
Total sales in the period. On the company page, quarterly bars or the trailing twelve months (TTM), which smooths seasonality.
Growing revenue with shrinking margins is a warning, not a win.
More on Imunon
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.